Standard BioTools Inc reports results for the quarter ended June 30 - Earnings Summary

Standard BioTools

11/08/2025 22:01

Standard BioTools Inc LAB.OQ reported a quarterly adjusted loss of 9 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -12 cents.  The mean expectation of three analysts for the quarter was for a loss of 8 cents per share. Wall Street expected results to range from -9 cents to -7 cents per share.

Revenue rose 12.8% to $41.96 million from a year ago; analysts expected $39.82 million.

Standard BioTools Inc's reported EPS for the quarter was a loss of 9 cents​.

The company reported a quarterly loss of $33.46 million.

Standard BioTools Inc shares had risen by 8.8% this quarter and lost 25.4% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

Wall Street's median 12-month price target for Standard BioTools Inc is $1.93, about 32.2% above its last closing price of $1.31

This summary was machine generated from LSEG data August 11 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.08
-0.09
Missed
Mar. 31 2025
-0.07
-0.07
Met
Dec. 31 2024
-0.07
-0.09
Missed
Sep. 30 2024
-0.09
-0.07
Beat